№ files_lp_4_process_3_104466
File format: docx Character count: 454 File size: 1395 KB
Clinical research document presenting survival outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma based on chemotherapy and Rituximab treatment regimens.
Year: Not specified
Region / City: Not specified
Theme: Oncology, Hematology
Document Type: Scientific Research
Organization / Institution: Not specified
Author: Not specified
Target Audience: Medical professionals, researchers
Action Period: Not specified
Approval Date: Not specified
Date of Changes: Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
A phase II trial of Bendamustine, Rituximab and Acalabrutinib in previously untreated Waldenström’s Macroglobulinemia (BRAWM)
Year: 2024
Country: Canada
Study Type: Phase II clinical trial
Treatment Regimen: Bendamustine-Rituximab combination with concurrent Acalabrutinib
Participants: 62
Centers: 9
Primary Endpoint: Combined Complete and Very Good Partial Response (CR+VGPR) rates
Secondary Endpoints: Best overall response (BoR), progression-free survival (PFS), overall survival (OS), duration of response (DoR), Minimal Residual Disease (MRD)
Median Age: 69
Mutation Analysis: MYD88 89.3%, CXCR4 28.6%, TP53 1.8%
Adverse Events: Treatment-related adverse events (TRAEs) in 53 participants, 42 Grade 3/4 during combination therapy, 15 Grade 3/4 during monotherapy
Follow-up: Median 350 days
Data Cut-off: June 5, 2024
Document Type: Clinical trial report
Topics: nodular lymphocyte-predominant Rituximab